TCL.AU

13.83

-0.14%↓

BXB.AU

-0.48%↓

ALQ.AU

17.11

-1.95%↓

WOR.AU

13.13

+0.92%↑

TCL.AU

13.83

-0.14%↓

BXB.AU

-0.48%↓

ALQ.AU

17.11

-1.95%↓

WOR.AU

13.13

+0.92%↑

TCL.AU

13.83

-0.14%↓

BXB.AU

-0.48%↓

ALQ.AU

17.11

-1.95%↓

WOR.AU

13.13

+0.92%↑

TCL.AU

13.83

-0.14%↓

BXB.AU

-0.48%↓

ALQ.AU

17.11

-1.95%↓

WOR.AU

13.13

+0.92%↑

TCL.AU

13.83

-0.14%↓

BXB.AU

-0.48%↓

ALQ.AU

17.11

-1.95%↓

WOR.AU

13.13

+0.92%↑

Home・Aktien・CSL Ltd

CSL Ltd

Open

BrancheIndustrie

242.51 1.2

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

239.51

Max

243.43

Schlüsselkennzahlen
By Trading Economics
Einkommen	2B
Verkäufe	-5.7B 2.5B
KGV Branchendurchschnitt	28.538 39.095
Dividendenrendite	1.77
Gewinnspanne	24.437
Angestellte	32,698
EBITDA	-2.4B 858M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+31.18% upside

Dividenden
By Dow Jones
Dividendenrendite Branchendurchschnitt	1.77% 2.47%
Nächstes Ergebnis	12. Aug. 2025

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-8.9B 116B
Vorheriger Eröffnungskurs	241.31
Vorheriger Schlusskurs	242.51

Nachrichtenstimmung

By Acuity

63%

37%

419 / 464 Ranking in Industrials

CSL Ltd Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

9. Apr. 2025, 09:39 UTC

Wichtige Markttreiber

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

10. Feb. 2025, 21:55 UTC

Ergebnisse

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business -- Update

10. Feb. 2025, 21:34 UTC

Ergebnisse

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business

12. Aug. 2024, 23:23 UTC

Ergebnisse

CSL Annual Profit Rises by 20% on Immunoglobulins Growth -- Update

12. Aug. 2024, 22:49 UTC

Ergebnisse

CSL Annual Profit Rises by 20%, Forecasts Fiscal Year 2025 Underlying Earnings Growth

17. Juni 2025, 02:15 UTC

Market Talk

Higher Margins Offered by CSL's Andembry Will Lift Earnings -- Market Talk

9. Apr. 2025, 07:01 UTC

Market Talk

CSL May Need to Raise Prices to Offset Trump's Potential Pharma Tariffs -- Market Talk

21. März 2025, 02:03 UTC

Market Talk

Severe U.S. Influenza Season Could Benefit CSL -- Market Talk

11. Feb. 2025, 22:30 UTC

Market Talk

Flu Vaccines Proving Problematic for CSL -- Market Talk

10. Feb. 2025, 21:40 UTC

Ergebnisse

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business -- Update

10. Feb. 2025, 21:19 UTC

Ergebnisse

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business

10. Feb. 2025, 21:13 UTC

Ergebnisse

CSL Reaffirms Guidance for FY 2025 Net Profit of US$3.2 Billion-US$3.3 Billion at Constant FX

10. Feb. 2025, 21:12 UTC

Ergebnisse

CSL Interim Dividend US$1.30/Security

10. Feb. 2025, 21:12 UTC

Ergebnisse

CSL 1H Revenue US$8.48 Billion, Up 5% on Year

10. Feb. 2025, 21:11 UTC

Ergebnisse

CSL 1H Net Profit US$2.07 Billion, Up 3% on Year

7. Nov. 2024, 03:53 UTC

Market Talk

U.S. Tariffs Could Force Moves by Australian Med-Techs -- Market Talk

22. Okt. 2024, 22:53 UTC

Market Talk

CSL's R&D Update Seen as Neutral Overall -- Market Talk

10. Okt. 2024, 22:20 UTC

Market Talk

CSL Bull Looking for Update on Gross Margin -- Market Talk

13. Aug. 2024, 00:33 UTC

Market Talk

CSL Profit Outlook Looks Weaker Than Expected -- Market Talk

12. Aug. 2024, 22:34 UTC

Ergebnisse

CSL Annual Profit Rises by 20%, Forecasts FY 2025 Underlying Earnings Growth

12. Aug. 2024, 22:18 UTC

Ergebnisse

CSL Expects FY2025 Revenue Growth of Roughly 5%-7% at Constant Currency

12. Aug. 2024, 22:18 UTC

Ergebnisse

CSL: Conditions for Seqirus Remain Challenging, But Unit Expected to Outperform Market

12. Aug. 2024, 22:17 UTC

Ergebnisse

CSL: Has a Number of Efficiency Initiatives Underway in Plasma Collections, Manufacturing Operations

12. Aug. 2024, 22:16 UTC

Ergebnisse

CSL: Momentum in Behring Seen Underpinned by Strong Patient Demand in Immunoglobulins

12. Aug. 2024, 22:15 UTC

Ergebnisse

CSL: Remains Confident in Medium-Term Double-Digit Earnings Growth Target

12. Aug. 2024, 22:14 UTC

Ergebnisse

CSL: Vifor Continues to Grow Iron Volume in Europe Despite Generic Entrants

12. Aug. 2024, 22:13 UTC

Ergebnisse

CSL Expects FY2025 Underlying Profit Up Between 10%-13% on Constant Currency Basis

12. Aug. 2024, 22:13 UTC

Ergebnisse

CSL Expects FY2025 Underlying Profit Between US$3.2 Billion-US$3.3 Billion

12. Aug. 2024, 22:11 UTC

Ergebnisse

CSL: Outlook for Behring Positive But Competitive Pressures Increased Recently

12. Aug. 2024, 22:10 UTC

Ergebnisse

CSL FY Underlying Profit Up 15% on Constant Currency Basis to US$3.01 Billion

Peer-Vergleich

Kursveränderung

CSL Ltd Prognose

Kursziel

By TipRanks

31.18% Vorteil

12-Monats-Prognose

Durchschnitt 312.524 AUD 31.18%

Hoch 330 AUD

Tief 303 AUD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für CSL Ltd – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

8 ratings

Buy

Halten

Sell

Basierend auf 8 Analysten, die in den letzten 3 Monaten Aktienbewertungen für CSL Ltd – Dist abgegeben haben.

Stimmung

By Acuity

419 / 464 Ranking in Industrie

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über CSL Ltd

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.